Starpax Biopharma

12:45 PM - 1:00 PM (EDT), Monday, June 5, 2023 ・ Session Room 104C
Starpax has developed a never before seen technology that guides in 3D Magnetodrones™ in tumors. The Magnetodrones™ consist of non-pathogenic, aerotactic and sensitive to magnetic fields proprietary living bacteria. They transport anticancer drug attached to their surface, and can swim in the interstitial spaces of tumor tissues. Magnetodrones™ are injected directly into the tumor and are guided by the patented PolarTrak™ magnetic fields, in which the patient is installed. The PolarTrak™ keeps them trapped inside the tumor and force them to distribute in 3D throughout the volume of the tumor, accumulate in hypoxic areas and delivering drug along their path, without circulating in the bloodstream. Magnetodrones die after 60 minutes.
The technology addresses solid tumors (90% of cancers) using already FDA approved drugs offering 3 therapeutic effects in a single treatment: 1) Localized Chemotherapy, 2) Hypoxic Zones Stem Cells Therapy, 3) Systemic Immunotherapy in the rest of the body.
Not Provided
Not Provided
Company Type:
Not Provided
Company HQ State:
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Cancer treatment for solid tumor (90% of cancers), The proprietary Magnetodrones and PolarTrack as explained in the Company description.
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
We are looking for investors.
Founding President, CEO
Starpax Biopharma